Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation

Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation

Background: Ex-vivo lung perfusion (EVLP) is an innovative platform for assessing donor lungs in the pre-transplant window. In this study, we demonstrate an extension of its utility by administering the anti-CD20 monoclonal antibody, Rituximab, during EVLP. We hypothesized that this would lead to ta...

Full description

Bibliographic Details
Main Authors: Terrance J.Y. Ku, Rafaela V.P. Ribeiro, Victor H. Ferreira, Marcos Galasso, Shaf Keshavjee, Deepali Kumar, Marcelo Cypel, Atul Humar
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EBioMedicine
Subjects:
Ex-vivo lung perfusion
Monoclonal therapy
Rituximab
Epstein-Barr virus
PTLD
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420303704

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420303704

Similar Items